QA102 Phase II Study in Subjects With Dry AMD (AMEND)

Smilebiotek Zhuhai

Status and phase

Completed

Phase 2

Conditions

Dry Age-related Macular Degeneration

Treatments

Drug: QA102

Drug: QA102/Placebo

Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT05536752

QA102-CS201

Details and patient eligibility

About

This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of soft drusen, visual acuity (VA), and geographic atrophy (GA) or choroidal neovascularization (CNV) or the progression of GA in subjects with intermediate to advanced dry AMD.

Full description

Approximately 30 sites will randomize a total of approximately 150 subjects to 1 of 3 treatment arms in a 1:1:1 ratio (50 subjects per arm). Each subject will receive either QA102 or matching placebo BID for up to 15 months.

Enrollment

150 patients

Sex

All

Ages

50+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

Subject must be able to understand and willing to sign a written informed consent form (ICF) prior to the initiation of any study-specific procedures.
Subject must be age ≥50 years at the time of informed consent.
Subject must be able to take oral medications and willing to record daily adherence to taking their assigned capsules.
Subject must have adequate hematologic function, hepatic function, renal function and coagulation profile as defined in the protocol.
Subject must be willing and able to comply with study procedures and examinations.

Specific to the Study Eye:

Subject must have one of the following:
- extensive intermediate-size drusen, or at least 1 large drusen, or
- GA ((not involving the foveal center point) secondary to AMD, with very limited aggregate size of total GA(s), as defined in the protocol.
Subject must be able to correctly identify ≥35 ETDRS letters (approximately 20/200 Snellen equivalent).

Specific to Fellow Eye:

Subject must have a diagnosis of advanced AMD (evidence of GA and/or CNV), to be confirmed by the CRC.

Specific to Both Eyes:

Subject must have visualizable retina, clear ocular media, and adequate pupillary dilation to ensure high-quality fundus imaging.

Key Exclusion Criteria:

Subject received an active investigational drug within 6 weeks (or 5 half-lives of the active, whichever is longer) prior to screening for this QA102 study.
Subject has ever received gene therapy (for any condition).
Subject is unwilling to stop intake of Age-Related Eye Disease Studies (AREDS) vitamins for the duration of the study.
Subject has a clinically significant systemic disease that might interfere with the study, in the judgment of the Investigator.
Subject had major surgery within 30 days prior to Screening.

Specific to Study Eye:

Subject has large GA, subfoveal GA, or active or inactive CNV, as confirmed by the CRC.
Subject has GA or CNV due to causes other than AMD that that developed between Visit 1 (Screening) and Visit 2 (Randomization).
Subject has endophthalmitis.
Subject has a hemorrhagic or serous pigment epithelial detachment (PED) within 500 µm of the foveal center point, to be confirmed by the CRC.
Subject has had retinal procedures or surgeries, or has a retinal pathology, such as a macular hole.
Subject has aphakia or absence of the posterior capsule.
Subject has ever received, whether in an interventional trial or by prescription, an FDA- approved treatment for GA. Use of such treatment during the QA102 study period also is prohibited. (Study Eye Only)

Specific to Fellow Eye:

Subject has monocular vision impairment, defined as having no light perception in the fellow eye with adequate vision in the study eye.

Specific to Either Eye:

Subject had intraocular surgery with lens replacement within 3 months of Screening.
Subject has any ophthalmic condition that could require surgery during the study period.
Subject has an ocular condition that might affect adequate imaging of the retina and/or or alter visual acuity.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

150 participants in 3 patient groups, including a placebo group

QA102 200mg group

Experimental group

Description:

Subjects randomized to this arm will receive one (1) 200 mg capsule of QA102 and 1 placebo capsule BID = daily dose of 400 mg QA102 for up to 15 months

Treatment:

Drug: QA102/Placebo

QA102 400mg group

Experimental group

Description:

Subjects randomized to this arm will receive two (2) 200 mg capsules of QA102 BID = daily dose of 800 mg QA102 for up to 15 months

Treatment:

Drug: QA102

Placebo group

Placebo Comparator group

Description:

Subjects randomized to this arm will receive two (2) placebo capsules BID = daily dose of 0 mg QA102 for up to 15 months